CD19⁺IgD⁺CD27⁻ naïve B Cells as predictors of humoral response to COVID-19 mRNA vaccination in immunocompromised patients

Eduard Schulz^{1*}, Isabel Hodl^{2*}, Patrick Forstner³, Stefan Hatzl¹, Nazanin Sareban⁴, Martina Moritz⁴, Johannes Fessler⁵, Barbara Dreö², Barbara Uhl¹, Claudia Url⁴, Andrea Grisold³, Michael Khalil⁶, Barbara Kleinhapp³, Christian Enzinger⁶, Martin H. Stradner², Hildegard Greinix¹, Peter Schlenke⁴ and Ivo Steinmetz³

*ES and IH contributed equally to the manuscript.

¹Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

²Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

³Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Graz, Austria

⁴Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria

⁵Institute of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria

⁶Department of Neurology, Medical University of Graz, Graz, Austria

Corresponding author:

Martin H. Stradner
Division of Rheumatology and Immunology
Department of Internal Medicine
Medical University of Graz
Auenbruggerplatz 15, 8036 Graz, Austria
Tel: +43/316/385-81794
Fax: +43/316/385-17813
E-mail: martin.stradner@medunigraz.at

The authors declare no competing financial interests.

Key words: mRNA vaccine, COVID-19, B cells, cancer, immunodeficiency

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Immunocompromised patients are considered high-risk and prioritized for vaccination against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential predictors of humoral vaccination response. Patients (n=120) suffering from hematologic malignancies or other causes of immunodeficiency and healthy controls (n=79) received a full vaccination series with an mRNA vaccine. B-cell subsets were analyzed prior to vaccination. Two independent anti-SARS-CoV-2 immunoassays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed three to four weeks after the second vaccination. Seroconversion occurred in 100% of healthy controls, in contrast to 67% (RBD) and 82% (TSP) of immunocompromised patients, while only 32% (RBD) and 22% (TSP) achieved antibody levels comparable to those of healthy controls. The number of circulating CD19⁺IgD⁺CD27⁻ naïve B cells was strongly associated with antibody levels ($p=0.761$, $P<0.001$) and the only independent predictor for achieving antibody levels comparable to healthy controls (OR 1.07 per 10- μ l increase, 95%CI 1.02–1.12, $P=0.009$). Receiver operating characteristic analysis identified a cut-off at ≥ 61 naïve B cells per μ l to discriminate between patients with and without an optimal antibody response. Consequently, measuring naïve B cells in immunocompromised hematologic patients could be useful in predicting their humoral vaccination response.

INTRODUCTION

Coronavirus disease 2019 (COVID-19) results in increased morbidity and mortality in immunocompromised patients.(1-3) Immunodeficiency can be primary (PID) due to underlying genetic causes such as common variable immunodeficiency or secondary (SID) resulting from hematologic malignancies (HM), immunosuppressive therapies, or hematopoietic stem cell transplantation (HSCT). In a recent study of 100 patients with COVID-19 disease, patients with PID and SID demonstrated higher morbidity and mortality than the general population, while the outcomes of individuals suffering from SID were the worst.(1) In patients with HM and COVID-19, a mortality rate of 34% (95% confidence interval [CI]: 28–39) has been reported in adults in a recent meta-analysis including 3377 predominantly hospitalized patients from 3 continents.(4) Interestingly, patients on systemic anticancer treatment had a similar risk of death compared to patients without therapy (RR 1.17, 95% CI: 0.83-1.64). Risk of death was highest in patients with acquired bone marrow failure syndromes (53%, 95% CI: 34-72), followed by acute leukemias (41%, 95% CI: 30-52), myeloproliferative neoplasms (34%, 95% CI: 19-51), plasma cell dyscrasias (33%, 95% CI: 25-41), lymphomas (32%, 95% CI: 18-48), and chronic lymphocytic leukemias (CLL) (31%, 95% CI: 23-40), respectively.

Patients with HM can be immunocompromised due to the underlying malignancy itself, prior or ongoing treatments with a high degree of immunosuppressive effects such as corticosteroids, B-cell depleting therapies, HSCT and other cellular therapies. In individuals with these risk factors, lower rates of seroconversion have been reported after COVID-19 infection whereas other cancer patients developed antibody response similar to healthy individuals.(5, 6) Roeker and colleagues observed that 67% of patients with CLL developed IgG antibodies to SARS-CoV-2 nucleocapsid and the seroconversion rate among recipients of HSCT and chimeric antigen receptor (CAR) T-cell therapy was similar at 66%.(7, 8)

Due to the high risk of severe COVID-19 in immunocompromised patients, they are considered a high priority for COVID-19 vaccination.(9-13) However, trials of the currently approved COVID-19 vaccines have excluded individuals diagnosed with immunodeficiency or malignancy; therefore, information on the efficacy and safety of the vaccines in these patients is sparse.(14-17) It is well known

that vaccinations in patients early after HSCT and anti-CD20 therapies as well as with several forms of PID have low efficacy.(18-20) The humoral immune response to a recombinant zoster vaccine in patients with B-cell lymphoma and CLL was between 20% and 50% compared to 80% in patients with other HM.(21)

Lack of antibody responses after COVID-19 vaccination and significantly lower antibody levels in responders have been reported in HM patient cohorts in general(5, 22, 23) and in selected patients with multiple myeloma, CLL, and non-Hodgkin's lymphoma.(24-28) Low efficacy of COVID-19 vaccinations was observed when administered soon after HSCT and anti-CD20 therapies.(9, 18, 19) Furthermore, immunocompromised patients due to inborn errors of immunity or autoimmune rheumatic disease (AIRD) demonstrated also reduced rates in seroconversion, especially when given B-cell-depleting therapy and glucocorticoids.(14-17)

Peripheral B cells are needed for humoral vaccination responses.(29) However, the number of circulating B cells or of a certain B-cell subset associated with a humoral vaccination response comparable to healthy individuals is unknown. A marker predictive of vaccination response would aid to schedule vaccinations in the immunocompromised patients to achieve an optimal vaccination response.

We hypothesize that specific B-cell subsets have to be present in immunocompromised individuals to enable a humoral vaccination response. Herein, we used data from an interim analysis of the prospective, open-label, phase IV CoVVac trial (NCT04858607) to test this hypothesis.

MATERIALS AND METHODS

Study design and participants

We report the data of an interim analysis of the CoVVac trial (NCT04858607), which is an ongoing open-label, phase IV, prospective, monocentric study at the Medical University of Graz, Austria. After approval by the ethics committee of the Medical University of Graz in April 2021 (EK 1128/2021), patients with inborn errors of immunity, hematological malignancies, those receiving B-cell-depleting therapy, and healthy controls were recruited before receiving their first dose of COVID-19 vaccine. The

detailed study protocol is provided in the Supplementary Information. In brief, blood was drawn before the first vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) for peripheral blood mononuclear cell (PBMC) isolation and lymphocyte phenotyping. The second vaccination was administered 21 (BNT162b2) or 28 days (mRNA-1273) after the first. Blood sampling was performed 21–28 days after the second vaccination to analyze the COVID-19-specific antibody response as the primary endpoint.

Lymphocyte phenotyping

Blood samples from the baseline visit were processed within 4 hours for analysis by flow cytometry. For lymphocyte phenotyping, ethylenediaminetetraacetic acid whole blood was stained for CD3, CD4, CD8, CD45, CD16, CD56, and CD19, as previously described.(30) For B-cell phenotyping, PBMCs were isolated from lithium heparin whole blood by Ficoll gradient density centrifugation. One million PBMCs were incubated with the following antibodies: CD19-VioGreen, anti-IgD-VioBlue, CD24-PerCP-Vio700, CD38-FITC, CD27-APC, CD86-PE-Vio770, CD21-APC-Vio770, and anti-IgM-PE (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were measured using a FACSLyric flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using the FACSSuite (BD Biosciences). The gating strategy is shown in Supplemental Figure 1.

Antibody assays

Blood was obtained before first and 21–28 days after the second vaccination. Serum was aliquoted, frozen, and stored at -80°C until analysis was performed in batches. Two commercially available CE-certified serological tests were performed according to the manufacturers' protocols to determine and quantify specific antibodies against SARS-CoV-2. Specific IgG was determined using the Roche Elecsys anti-SARS-CoV-2 S electrochemiluminescence immunoassay targeting the receptor-binding domain of the viral spike protein using a Cobas e 801 analytical unit (Roche Diagnostics GmbH, Mannheim, Germany).(27, 29) Its quantification range lies between 0.4 and 2500 U/ml, with a cut-off of 0.8 U/ml for positivity. Specific IgG was measured by Liaison SARS-CoV-2 TrimericS IgG test on Liaison XL (DiaSorin, Saluggia, Italy), which is a chemiluminescence immunoassay quantifying

antibodies that target the trimeric S protein.(28) Results are provided in binding antibody units (BAU) with a quantification range of 4.81–2080 BAU/ml. Values ≥ 33.8 BAU/ml were considered positive.

Statistical analysis

All statistical analyses were performed using Stata 16.1 (Stata Corp., Houston, TX, USA). Continuous data were reported as medians (25th–75th percentile) and categorical data as absolute frequencies (%). Correlations and associations between antibody response and other variables were examined using Spearman's rank-based correlation coefficients, rank-sum test, and χ^2 -squared tests. R^2 -statistics were obtained from multiple linear regression models with antibody response as the dependent variable. The optimal cut-off to separate patients with and without vaccination response was assessed by employing a maximized Youden's index within a receiver operating characteristic (ROC) analysis. Logistic models were used for univariate and multivariate modeling of the vaccination response. The Kruskal–Wallis test was used for continuous variables when comparing three or more treatment groups. The Kruskal–Wallis H test was used as a post-hoc test to determine between-group differences.

RESULTS

Study population

Data of 199 study participants who completed their full vaccination schedule were included in the efficacy analysis. Of these, 79 were healthy participants and 120 were immunocompromised patients. All study participants were vaccinated with mRNA-1273, with only two healthy individuals (1%) receiving BNT162b2. A total of 140 adverse events occurred after vaccination, with the most common being pain at the injection site, headache, fever, and fatigue. Four severe adverse events (hospitalization and death due to HM and bone fractures) were considered unrelated to vaccination. Participant characteristics are listed in Table 1. Diagnoses, immunosuppressive treatments, and antibody responses for subgroups are detailed in Supplementary Table 1.

Table 1.

Variable	Healthy (n=79)	Immunocompromised (n=120)	P
Age (years)	51 [36-56]	58 [50-65]	<0.001
Female gender n (%)	45 (57)	65 (54)	0.698
Body mass index (kg/m ²)	23.7 [21.6-26.4]	24.8 [22.7-27.8]	0.039
Vaccine			0.080
mRNA-1273 (Moderna)	77 (97)	120 (100)	
BNT162b2 (BioNTech/Pfizer)	2 (3)	0 (0)	
Immunodeficiency group			n/a
Primary immunodeficiency n (%)		25 (21)	
Autoimmune disease n (%)		39 (32)	
Hematologic disease n (%)		56 (47)	
B-cell depleting therapy			n/a
None n (%)		44 (37)	
Rituximab n (%)		35 (29)	
Ocrelizumab n (%)		6 (5)	
HSCT n (%)		35 (29)	
Days since B-cell depletion		166 [69-545]	

Table 1. Baseline characteristics of the study population. Data are reported as medians [25th-75th percentile] and absolute frequencies (%). P-values are from rank-sum tests, χ^2 -tests, and Fisher's exact tests, as appropriate. Significant P-values are highlighted in bold type. Abbreviations: n, number; HSCT, hematopoietic stem cell transplantation

Immunogenicity of mRNA vaccines

Antibody responses were assessed using two different assays. All healthy controls demonstrated seroconversion with high antibody titers (Roche median: 2500 U/ml; DiaSorin median: 2080 BAU/ml). In immunocompromised patients, the seroconversion rates and antibody levels were significantly lower than those in healthy controls (Table 2 and Figure 1); 67% (n = 80) and 82% (n = 98) of patients demonstrated a humoral response with antibody levels within the quantification range of Roche and DiaSorin assays, respectively. Since the clinical significance of antibody levels close to the limit of detection was unclear, we defined more stringent thresholds for our patients, namely a "stringent response" as reaching at least the lowest antibody level of the healthy individuals from our cohort (Roche ≥ 1000 U/ml; DiaSorin ≥ 2000 BAU/ml). According to this definition, only 32% (Roche) and 22%

(DiaSorin) of patients had a stringent antibody response. This difference was not statistically significant between the two tests ($P = 0.108$). Patients who received anti-CD20 therapy, including the majority of patients with AIRD, had the lowest rate of stringent response ($\leq 10\%$). Interestingly, patients who received HSCT demonstrated a relatively high rate of stringent response [37% (13/35)]. There was no statistically significant difference between allogeneic and autologous HSCT (40% vs. 30%, respectively; $P = 0.541$). The antibody levels of both assays showed an excellent correlation with each other in the patient population ($\rho = 0.915$, $P < 0.001$, $R^2 = 0.841$; Table 2; Figure 2A), as well as in the entire study population (Supplementary Figure 2A). Since the Roche assay is more widely used in research and shows a good correlation with live virus neutralization tests in vaccinated individuals (22, 27, 29, 31), we focused on the Roche assay for subsequent analyses to ensure comparability with other studies.

Table 2.

	Healthy (n=79) N (%)	Immunocompromised (n=120) N (%)	P
Roche any response	79 (100)	80 (67)	<0.001
Roche stringent response	79 (100)	38 (32)	<0.001
Roche U/ml	2500 [2500-2500]	67 [0-1947]	<0.001
DiaSorin any response	79 (100)	98 (82)	<0.001
DiaSorin stringent response	79 (100)	26 (22)	<0.001
DiaSorin BAU/ml	2080 [2080-2080]	233 [12-1760]	<0.001

Table 2. Antibody Response to Vaccination. Data are reported as medians [25th-75th percentile] and absolute frequencies (%). P-values are from rank-sum tests, χ^2 -tests, and Fisher's exact tests, as appropriate. Significant P-values are highlighted in bold type. Any response, any seroconversion; BAU, binding antibody unit; DiaSorin stringent response, DiaSorin SARS-CoV-2 TrimericS IgG ≥ 2000 BAU/ml; HSCT, hematopoietic stem cell transplantation; Roche stringent response, Roche anti-SARS-CoV-2 S total antibody titer ≥ 1000 U/ml.

Correlation of antibody levels with the amount of B-cell subsets

The total number of B cells and all B-cell subsets prior vaccination were positively correlated with the antibody levels in all patients (Roche: $\rho = 0.739$, $R^2 = 0.001$, $P < 0.001$; Table 3; Figure 2B). In this analysis, the absolute number of naïve B cells showed the highest correlation with antibody titers (Roche: $\rho = 0.761$, $R^2 = 0.153$; Figure 2C). Furthermore, this analysis also indicated that the time between last B-cell-depleting therapy and vaccination was also a significant factor correlating with antibody levels. Extending this correlation analysis to the entire study population (Supplementary Figure 2), the influence of naïve B cells remained highly significant (Roche: $\rho = 0.636$, $P < 0.001$, $R^2 = 0.123$).

To support the results of our correlation analyses, we established a model of stringent vaccination response prediction for the entire study population based on the results of the Roche assay using the area under the ROC curve (AUC; Supplementary Table 2). This model suggests that the total number of CD19⁺ B cells (AUC: 0.87, 95% CI: 0.79–0.92), CD19⁺IgD⁺CD27⁻ naïve B cells (AUC: 0.82, 95% CI: 0.73–0.88), CD19⁺IgD⁺CD27⁺ pre-switched memory B cells (AUC: 0.84, 95% CI: 0.76–0.89), and CD19⁺IgD⁻CD27⁺ switched memory B cells (AUC: 0.85, 95% CI: 0.79–0.91) can predict response to vaccination in the entire study population.

155 **Table 3.**

Variable	Roche anti-SARS-CoV-2		
	ρ	P	R ²
DiaSorin SARS-CoV-2 TrimericS IgG	0.915	<0.001	0.841
Age	0.091	0.321	0.001
Body mass index	0.169	0.076	0.004
Days since last B-cell depletion	0.595	<0.001	0.041
Interval in days from last B-cell depleting therapy to vaccination up to 365 days	0.481	0.001	0.096
IgA	0.042	0.651	0.015
IgG	0.065	0.481	0.031
IgM	0.386	<0.001	0.002
Lymphocytes abs.	0.222	0.018	0.002
CD3 ⁺ cells abs.	0.112	0.236	0.034
CD3 ⁺ CD8 ⁺ cells abs.	0.170	0.071	0.005
CD3 ⁺ CD4 ⁺ cells abs.	0.025	0.789	0.062
CD3 ⁻ CD16 ⁺ CD56 ⁺ NK cells abs.	-0.014	0.880	0.014
CD19 ⁺ abs.	0.739	<0.001	0.001
CD45 ⁺ cells abs.	0.227	0.015	0.002
CD19 ⁺ IgM ⁺ CD38 ⁺⁺ transitional B cells abs.	0.491	<0.001	0.033
CD19 ⁺ IgD ⁺ CD27 ⁻ naïve B cells abs.	0.761	<0.001	0.153
CD19 ⁺ IgD ⁺ CD27 ⁺ pre-switched memory B cells abs.	0.657	<0.001	0.004
CD19 ⁺ IgD ⁻ CD27 ⁺ switched memory B cells abs.	0.710	<0.001	0.003
CD19 ⁺ CD38 ⁻ CD21 ⁻ B cells abs.	0.640	<0.001	0.001
CD19 ⁺ IgM ⁻ CD38 ⁺⁺ plasmablasts abs.	0.580	<0.001	0.001

156 **Table 3.** Correlations of SARS-CoV-2 antibody response with variables in the
157 immunocompromised study population. Correlations were computed with Spearman's rank-based rho
158 adjusted for multiple testing (n=21) with Šidák correction. The Šidák-adjusted α level is approximately
159 0.00244. Significant P-values are highlighted in bold type. Abs., absolute count.

CD19⁺IgD⁺CD27⁻ naïve B cells show the strongest association with stringent response

To test the association of variables with vaccination response determined by the Roche assay, we performed univariate and multivariate linear regression analyses using the same variables from the correlation analyses.

In univariate analysis (Table 4), the variables found to be significantly associated with any antibody response in patients included interval in days from the last B-cell-depleting therapy, CD19⁺IgD⁺CD27⁻ naïve B-cell count, CD19⁺IgD⁺CD27⁺ pre-switched memory B-cell count, and absolute number of CD19⁺IgM⁻CD38⁺⁺ plasmablasts. The same correlation was also found for stringent antibody responses, except for the correlation with CD19⁺IgD⁺CD27⁺ pre-switched memory B cells. The absolute number of these B-cell subsets was significantly lower in immunocompromised patients than in healthy controls, in patients after anti-CD20 antibody therapy compared to HSCT, and in patients without seroconversion compared to those with any antibody response (not shown) or stringent response (Supplementary Figure 3). Immunoglobulin levels and cell counts of immunodeficient patients stratified by vaccination response are shown in Supplementary Table 3. In univariate analysis of the entire study population (Supplementary Table 4), the same B-cell subsets remained significantly associated with vaccine response.

In multivariable analysis for stringent response, only the number of CD19⁺IgD⁺CD27⁻ naïve B cells was an independent predictor (OR: 1.07 per 10-μl increase, 95% CI: 1.02–1.12, P = 0.009). The only independent predictor of any seroconversion was CD19⁺IgM⁻CD38⁺⁺ plasmablast count (OR: 4.42 per 1-μl increase, 95% CI: 1.30–15.01, P = 0.017).

The multivariable analyses for the entire study population are shown in Supplementary Tables 5 and 6. The absolute number of CD19⁺IgD⁺CD27⁻ naïve B cells remained an independent predictor of stringent antibody response (OR: 1.14 per 10-μl increase, 95% CI: 1.08–1.20, P<0.001).

186

187 **Table 4.**

Variable	Any Response			Stringent Response		
	OR	95% CI	P	OR	95% CI	P
Age (per 10 years)	1.23	0.92-1.66	0.167	1.02	0.76-1.38	0.880
Body mass index (per 5 point)	1.20	0.77-1.87	0.420	1.11	0.71-0.73	0.633
Interval in days from last B-cell depleting therapy to vaccination up to 365 days (per 30 days)*	1.41	1.13-1.76	0.002	1.31	1.02-1.67	0.035
IgA (per 1g/l)	0.74	0.50-1.10	0.136	1.30	0.87-1.93	0.199
IgG (per 5g/l)	0.96	0.62-1.49	0.848	1.43	0.90-2.27	0.127
IgM (per 1g/l)	1.32	0.83-2.10	0.246	0.98	0.92-1.05	0.677
Lymphocytes abs. (per 1 G/l)	0.94	0.81-1.10	0.461	1.03	0.89-1.18	0.686
CD3 ⁺ cells abs. (per 10/ μ l)	1.00	0.99-1.01	0.693	1.00	0.99-1.01	0.101
CD3 ⁺ CD8 ⁺ cells abs. (per 10/ μ l)	1.01	0.99-1.02	0.143	1.00	0.99-1.01	0.846
CD3 ⁺ CD4 ⁺ cells abs. (per 10/ μ l)	0.99	0.98-1.01	0.403	1.01	1.00-1.02	0.009
CD3 ⁻ CD16 ⁺ CD56 ⁺ NK cells abs. (per 10/ μ l)	0.98	0.96-1.01	0.139	1.01	0.99-1.03	0.180
CD19 ⁺ abs. (per 10/ μ l)	0.99	0.99-1.01	0.401	0.99	0.99-1.01	0.931
CD45 ⁺ cells abs. (per 10/ μ l)	0.99	0.99-1.01	0.045	1.00	0.99-1.01	0.653
CD19 ⁺ IgM ⁺ CD38 ⁺⁺ transitional B cells abs. (per 1/ μ l)	1.17	0.97-1.42	0.094	1.05	0.96-1.15	0.233
CD19 ⁺ IgD ⁺ CD27 ⁻ naïve B cells abs. (per 10/ μ l)	1.17	1.07-1.28	0.001	1.09	1.04-1.14	<0.001
CD19 ⁺ IgD ⁺ CD27 ⁺ pre-switched memory B cells abs. (per 10/ μ l)	1.78	1.09-2.92	0.021	1.03	0.95-1.11	0.480

CD19 ⁺ IgD ⁺ CD27 ⁺ switched memory B cells abs. (per 10/ μ l)	0.99	0.99-1.01	0.406	0.99	0.99-1.00	0.957
CD19 ⁺ CD38 ⁺ CD21 ⁻ B cells abs. (per 10/ μ l)	0.99	0.98-1.01	0.512	1.00	0.99-1.01	0.746
CD19 ⁺ IgM ⁺ CD38 ⁺⁺ plasmablasts abs. (per 1/ μ l)	7.95	2.68-23.4	<0.001	1.85	1.24-2.74	0.002

Table 4. Univariate linear regression analysis to test the association of variables with vaccination response determined by the Roche anti-SARS-CoV-2 S assay in the immunodeficient cohort. Significant P-values are highlighted in bold type. Any response, any seroconversion; OR, odds ratio; stringent response, total antibody titer ≥ 1000 U/ml. Abs., absolute count.

Exploratory analyses

As CD19⁺IgD⁺CD27⁻ naïve B cells were the only B-cell subset independently associated with stringent antibody response, we were interested to determine whether our dataset allowed to estimate a CD19⁺IgD⁺CD27⁻ naïve B cell count threshold for stringent antibody response. ROC analysis and non-linear risk modeling predicted that ≥ 61 CD19⁺IgD⁺CD27⁻ naïve B cells per μ l discriminated best between patients with and without a stringent vaccine response (Figures 3A, B).

A second exploratory ROC analysis was undertaken to determine the minimum interval between last B-cell-depleting therapy, i.e., anti-CD20 antibody therapy or HSCT up to 365 days (n = 53), and vaccination differentiating any seroconversion versus no vaccination response. The optimal cut-off in this population was 116 days or more (Figure 3C).

DISCUSSION

Since the presence of B cells is a prerequisite for humoral vaccination responses, we investigated B cells overall and multiple B-cell subsets in immunocompromised patients and healthy controls prior to COVID-19 mRNA vaccination.

Our findings confirm recent reports observing significantly lower and more heterogeneous anti-SARS-CoV-2 S protein IgG titers in immunocompromised patients compared to healthy controls.(14, 15, 22, 24-29) In one of the largest studies, Maneikis and colleagues reported lower median anti-S1 IgG responses after two BNT162b2 vaccine doses in 653 patients with HM compared to 69 healthy healthcare workers.(23) A similar heterogeneity in vaccination response has been observed in patients with PID,(14) AIRD,(16) and individuals given anti-CD20 therapy.(22, 23, 27, 32) In view of the heterogeneity of anti-SARS-CoV-2 antibody levels and the current lack of knowledge regarding the clinical consequences of low versus high titers in immunocompromised patients, we additionally analyzed stringent vaccination response defined as the lowest anti-SARS-CoV-2 antibody titers observed in our healthy control assuming that these would be protective. Based on this definition, only 32% (Roche) and 22% (DiaSorin) of our patients demonstrated a stringent antibody response, respectively. Longitudinal studies are on their way to assess durability of anti-SARS-CoV-2 humoral responses as well as incidences of COVID-19 infections in patients with or without stringent humoral response.

In our study, absolute numbers of CD19⁺IgD⁺CD27⁻ naïve B cells, CD19⁺IgD⁺CD27⁺ pre-switched memory B cells, and CD19⁺IgM⁺CD38⁺⁺ plasmablasts were significantly associated with anti-SARS-CoV-2 response in univariate analysis. However, only the number of CD19⁺IgD⁺CD27⁻ naïve B cells was an independent predictor of a stringent vaccination response in multivariable analysis, suggesting their functional importance for obtaining a humoral immune response. Indeed, the production of specific antibodies to a novel antigen relies on the presence of antigen-specific B cells within the CD19⁺IgD⁺CD27⁻ naïve B cell population.(33) Thus, a drastically contracted pool of CD19⁺IgD⁺CD27⁻ naïve B cells reduces the chance of harboring B cells with a B-cell receptor of high antigen avidity that can interact with T follicular helper cells successfully and subsequently undergo somatic hypermutation to develop an optimal antibody response.(34) A lack of these cells results in low antibody titers of poor quality. Therefore, the association of the magnitude of the humoral vaccination response with the abundance of CD19⁺IgD⁺CD27⁻ naïve B cells is most likely a causal relationship.

To date, there is little literature on this topic, and we are the first to describe this relationship, particularly in the context of COVID-19 and immunocompromised patients. The importance of naïve B cells for

antibody response has already been shown for the H5N1 influenza vaccine, but to the best of our knowledge not yet for immunocompromised patient cohorts or COVID-19 in particular.(35) Recently, Redjoul and colleagues reported a significant increase in anti-SARS-CoV-2 antibodies in 42 HM patients given a third dose of BNT162b2 vaccine after allogeneic HSCT.(36) In a multivariable analysis, only a peripheral B-cell count of more than 250/ μ l at the time of the third vaccination was associated with humoral response (OR 7.1, 95% CI: 1.5-34.1, P=0.016).(36) Mrak et al. observed that the percentage of peripheral CD19⁺ B cells positively correlated with antibody levels after BNT162b2 vaccination (τ =0.4, P<0.001) in patients with AIRD after rituximab therapy.[24] The median percentage of peripheral CD19⁺ B cells was 2% (interquartile range [IQR], 0-33) in the study of Mrak et al., which is not very different from 4% (IQR, 0-13) in our patient population. Our results extend these findings and show that only CD19⁺IgD⁺CD27⁻ naïve B cells predicted a strong vaccination response.

How soon humoral immune responses may be expected after B-cell depleting therapy remains a concern, and recommendations of medical societies differ. Our data confirm that the interval between the last B-cell-depleting therapy and SARS-CoV-2 vaccination plays a crucial role in achieving seroconversion for immunocompromised patients. We were able to define a minimum of 116 days, i.e. 4 months, from last B-cell-depleting therapy to vaccination as prerequisite for obtaining an anti-SARS-CoV-2 seroconversion.

Whereas patients after allogeneic HSCT have high numbers of CD19⁺IgD⁺CD27⁻ naïve B cells, this B-cell subpopulation was significantly lower in individuals suffering from chronic graft-versus-host disease (GVHD).(37) Long-term clinical efficacy of rituximab could be demonstrated in chronic GVHD patients recovering naïve B cells after treatment. These findings are consistent with clinical responses to rituximab reported in patients with rheumatoid arthritis, SLE, and mixed cryoglobulinemia who recovered B cells.(38-40) Thus, rise in absolute numbers of B cells as well as CD19⁺IgD⁺CD27⁻ naïve B cells might indicate immune reconstitution after immunosuppressive therapies enabling achievement of a humoral immune response to SARS-CoV-2 vaccination. Contrarily, patients with a deficit of CD19⁺IgD⁺CD27⁻ naïve B cells may benefit more from continuation of strict hygiene measures as recommended by scientific organizations. Whether these immunocompromised patients will

substantially benefit from a third vaccination, must be demonstrated since first data of HSCT patients showed only low antibody titers in half of the patients.(36)

Our study had several limitations. These include single-center design and limited representation of some patient cohorts that do not allow clear conclusions on seroconversion rates among less common entities or less frequently used treatment strategies. Moreover, we cannot comment on the persistence of the observed vaccination response at this point. Our study relies on the measurement of antibodies as a surrogate for immunity to SARS-CoV-2. However, our results do not significantly differ between the two internationally deployed anti-spike protein serological assays for detecting either total Ig or IgG. Both tests showed a high correlation with surrogate neutralization tests, and Roche's assay correlated well with live virus neutralization tests in vaccinated individuals.(29, 31) The strength of our study is its prospective design and the introduction of the stringent vaccination response as a potentially clinically more relevant concept than seroconversion.

In summary, humoral response to SARS-CoV-2 mRNA vaccine is impaired in immunocompromised patients. The abundance of circulating CD19⁺IgD⁺CD27⁻ naïve B cells is strongly associated with an improved antibody vaccine response across different diseases and therapies. Therefore, measuring CD19⁺IgD⁺CD27⁻ naïve B cells may allow prediction of a humoral response to COVID-19 vaccination in immunocompromised patients. Further research is needed to confirm these findings for vaccinating immunocompromised individuals against COVID-19 and other pathogens.

Acknowledgments

We thank Pia-Carina Gallaun and Julia Lodron for technical assistance. The samples/data used for this project were processed with the help of the Biobank Graz of the Medical University of Graz, Austria.

Competing Interests

None of the contributing authors have a conflict of interest, including specific financial interests, relationships, and affiliations relevant to the topic or materials covered in the manuscript.

Author contributions

IH, ES, PS, SH, HG, IS, and MHS designed the study. ES, IH, PF, NS, JF, BD, BU, AG, MM, CU, MK, CE and BK collected clinical samples and/or data. PF and BK performed antibody assays. ES and SH

analyzed the data and performed the statistical analysis. ES, SH, IH, PS, HG, IS, and MHS critically reviewed and discussed the results. ES, IH, PF, HS, HG, and MHS wrote the first draft. All authors reviewed the draft and approved the final version of the manuscript.

REFERENCES

1. Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. *J Allergy Clin Immunol* 2021; **147**: 870,875.e1.
2. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, *et al.* Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet* 2020; **395**: 1907-18.
3. Hatzl S, Eisner F, Schilcher G, Kreuzer P, Gornicec M, Eller P, *et al.* Response to "COVID-19 in persons with haematological cancers". *Leukemia* 2020; **34**: 2265-70.
4. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, *et al.* Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood* 2020; **136**: 2881-92.
5. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, *et al.* Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell* 2021;.
6. Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, *et al.* Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol* 2021; **32**: 113-9.
7. Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, *et al.* Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. *Leukemia* 2020; **34**: 3047-9.
8. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, *et al.* Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. *J Clin Invest* 2020; **130**: 6656-67.

311 9. Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, *et al.* COVID-19 vaccine-readiness
312 for anti-CD20-depleting therapy in autoimmune diseases. *Clin Exp Immunol* 2020; **202**: 149-61.

313 10. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, *et al.* Priority COVID-19
314 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. *Cancer Discov* 2021; **11**: 233-
315 6.

316 11. van der Veldt, A A M, Oosting SF, Dingemans AC, Fehrmann RSN, GeurtsvanKessel C, Jalving M,
317 *et al.* COVID-19 vaccination: the VOICE for patients with cancer. *Nat Med* 2021; **27**: 568-9.

318 12. Ameratunga R, Longhurst H, Steele R, Lehnert K, Leung E, Brooks AES, *et al.* Common Variable
319 Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic
320 COVID-19. *J Allergy Clin Immunol Pract* 2021;.

321 13. Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, *et al.* Point of view
322 on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
323 *RMD Open* 2021; **7**: e001594. doi: 10.1136/rmdopen-2021.

324 14. Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, *et al.* Immunogenicity of Pfizer-
325 BioNTech COVID-19 vaccine in patients with inborn errors of immunity. *J Allergy Clin Immunol* 2021;.

326 15. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryas S, Toledano K, *et al.* Disease activity
327 and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer
328 mRNA vaccine against SARS-CoV-2. *Ann Rheum Dis* 2021;.

329 16. Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, *et al.* Immunogenicity and safety
330 of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory
331 rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis* 2021;.

332 17. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, *et al.* Effect of
333 Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective
334 Cohort Study. *Ann Intern Med* 2021;.

18. Jaffe D, Papadopoulos EB, Young JW, O'reilly RJ, Prockop S, Kernan NA, *et al.* Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. *Blood* 2006; **108**: 2470-5.
19. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, *et al.* 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014; **58**: e44-100.
20. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena, M T, *et al.* International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract* 2016; **4**: 38-59.
21. Dagnev AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, *et al.* Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. *Lancet Infect Dis* 2019; **19**: 988-1000.
22. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell* 2021;.
23. Maneikis K, Šablauskas K, Ringelevičiūtė U, Vaitekėnaitė V, Čekauskienė R, Kryžauskaitė L, *et al.* Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol* 2021; **8**: e583-92.
24. Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, *et al.* Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. *Br J Haematol* 2021;.
25. Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, *et al.* Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol* 2021; **8**: e389-92.

357 26. Gavriatopoulou M, Terpos E, Kastritis E, Briasoulis A, Gumeni S, Ntanas-Stathopoulos I, *et al.*
358 Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the
359 BNT162b2 and AZD1222 vaccine. *Clin Exp Med* 2021;; 1-5.

360 27. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, *et al.* Efficacy of the BNT162b2
361 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood* 2021; **137**: 3165-73.

362 28. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, *et al.* Fifth-week
363 immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma
364 and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J*
365 *Hematol Oncol* 2021; **14**: 81-021.

366 29. Mrak D, Tobudic S, Koblishke M, Graninger M, Radner H, Sieghart D, *et al.* SARS-CoV-2
367 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence
368 of T-cell-mediated immunity. *Ann Rheum Dis* 2021;.

369 30. Stradner MH, Dejaco C, Brickmann K, Graninger WB, Brezinschek HP. A combination of cellular
370 biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational
371 study. *Arthritis Res Ther* 2016; **18**: 190-016.

372 31. Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, *et al.* Anti-
373 Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five
374 Quantitative Assays. *Microbiol Spectr* 2021;; e0024721.

375 32. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, *et al.* BNT162b2
376 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J*
377 *Hematol* 2021;.

378 33. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*
379 2009; **9**: 185-94.

34. Chan TD, Brink R. Affinity-based selection and the germinal center response. *Immunol Rev* 2012; **247**: 11-23.
35. Ellebedy AH, Nachbagauer R, Jackson KJL, Dai YN, Han J, Alsoussi WB, *et al.* Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. *Proc Natl Acad Sci U S A* 2020; **117**: 17957-64.
36. Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. *Lancet Haematol* 2021; **8**: e681-3.
37. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, *et al.* Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. *Blood* 2009; **113**: 3865-74.
38. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. *Arthritis Rheum* 2006; **54**: 613-20.
39. Saadoun D, Rosenzweig M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. *Blood* 2008; **111**: 5334-41.
40. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, *et al.* Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. *Arthritis Rheum* 2004; **50**: 3580-90.

FIGURE LEGENDS

Fig 1. Immune response to SARS-CoV-2 mRNA vaccination. The scatter plot shows total immunoglobulin levels for healthy controls, immunodeficient patients and patients after anti-CD20 therapy or hematopoietic stem cell transplantation (HSCT). P is <0.001 between all groups calculated with the Kruskal-Wallis test and post hoc analysis. Lines are medians with interquartile range. The Plot was drawn with GraphPad Prism Version 9.2.0.332.

Fig 2. Correlation of antibody levels determined by Roche anti-SARS-CoV-2 S assay. (A) DiaSorin SARS-CoV-2 TrimericS IgG. (B) Absolute number of B cells (CD19⁺ cells). (C) Absolute number of naïve B cells. Scatter plots indicate a linear regression line including a 95% confidence interval. In case of A and B, regression line corresponds to transformed data using $x=\log((x+1))$ and $y=\log((y+1))$, respectively.

Fig 3. Exploratory analyses estimating the number of naïve B cells and the interval to the last B-cell depleting therapy required for a vaccination response. (A) The receiver operating characteristic (ROC) analysis curve for naïve B cells differentiating stringent antibody response vs no or any vaccination response in the whole study population (n=199) shows excellent discrimination. (B) A non-linear risk model based on the observed risk of seroconversion was created to estimate the minimum number of naïve B cells required for a stringent vaccination response. Independently, the best discriminatory cut-off (dashed line) was determined with the Youden's index from the ROC curve. Both models predict that ≥ 60 naïve B cell per μl are required to generate a stringent vaccine response. (C) The ROC analysis curve for the interval since the last B-cell depleting therapy up to 365 days (n=53) differentiating any seroconversion vs no vaccination response. The optimal cut-off is an interval of 116 days or more.

Roche anti-SARS-CoV-2 S total Ig [U/mL]

Figure 2

Figure 3

A

B

C